- Home
- ACTG vs AUTL Comparison
ACTG vs AUTL Comparison
Compare ACTG & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACTG | AUTL |
|---|---|---|
| Founded | 1993 | 2014 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 384.9M | 433.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ACTG | AUTL |
|---|---|---|
| Price | $4.01 | $1.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 210.7K | ★ 1.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $127.75 | $670.78 |
| Revenue Next Year | N/A | $80.13 |
| P/E Ratio | $81.01 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.70 | $1.11 |
| 52 Week High | $4.41 | $2.70 |
Technical Indicators
Market Signals| Indicator | ACTG | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 55.27 | 56.75 |
| Support Level | $3.93 | $1.36 |
| Resistance Level | $4.10 | $1.48 |
| Average True Range (ATR) | 0.15 | 0.08 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 48.39 | 91.07 |
Price Performance
Historical ComparisonAbout ACTG Acacia Research Corporation (Acacia Tech)
Acacia Research Corp is focused on acquiring and operating businesses across the industrial, energy, and technology sectors where it believes it can leverage its expertise, capital base, and deep industry relationships to drive value. The company has four reportable business segments: Intellectual Property Operations, Industrial Operations, Energy Operations and Manufacturing Operations. It derives revenue from Intellectual Property Operations segment. Geographically, it operates in Americas, Europe, Middle East and Africa, China, India, and Asia-Pacific, excluding China and India.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.